Advertisement

Breast Cancer Research and Treatment

, Volume 166, Issue 2, pp 541–547 | Cite as

Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study

  • Anne BlaesEmail author
  • Heather Beckwith
  • Natalia Florea
  • Robert Hebbel
  • Anna Solovey
  • David Potter
  • Douglas Yee
  • Rachel Vogel
  • Russell Luepker
  • Daniel Duprez
Clinical trial

Abstract

Purpose

Aromatase inhibitors (AI) have been shown to reduce breast cancer-related mortality in women with estrogen positive (ER+) breast cancer. The use of AIs, however, has been associated with higher rates of hypertension, hyperlipidemia, and cardiovascular (CV) events.

Methods

A cross-sectional study of 25 healthy postmenopausal women and 36 women with curative intent breast cancer on an AI was performed to assess endothelial dysfunction, an indicator of risk for CV events. Consented subjects underwent vascular testing using the HDI/Pulse Wave CR-2000 Cardiovascular Profiling System and the EndoPAT2000 system.

Results

Mean age was 61.7 and 59.6 years (cases, controls). Most subjects were Caucasian and overweight. Controls had a lower mean systolic blood pressure (128.6 mmHg vs. 116.2 mmHg, p = 0.004). Median estradiol levels were reduced in cases (2 vs. 15 pg/ml, p < 0.0001). EndoPAT ratio (0.8 vs. 2.7, p < 0.0001) was significantly reduced in cases as compared to controls. Median large artery elasticity (12.9 vs. 14.6 ml/mmHg × 10, p = 0.12) and small artery elasticity (5.2 vs. 7.0 ml/mmHg × 100, p = 0.07) were also reduced though not statistically significant. There was no correlation between use of chemotherapy, radiation therapy, type of AI, or duration of AI use and endothelial function. When adjusting for differences in blood pressure, results remained significant.

Conclusion

Breast cancer cases on AIs have reductions in endothelial function, a predictor of adverse CV disease. Impact: Vascular function changes in breast cancer cases on AIs compared to postmenopausal women. Further work is needed to evaluate vascular changes over time.

Keywords

Cardiotoxicity Breast cancer Aromatase inhibitors Endothelial function Vascular function 

Notes

Funding

The work in this paper was supposed by the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) NIH# K12-HD055887 Grant.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A et al (2017) NCCN guidelines insights: breast cancer, Version 1.2017. J Natl Compr Canc Netw 15(4):433–451CrossRefPubMedGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. doi: 10.1016/S0140-6736(11)61625-5 CrossRefGoogle Scholar
  3. 3.
    Hooning MJ, Dorresteijn LD, Aleman BM, Kappelle AC, Klijn JG, Boogerd W et al (2006) Decreased risk of stroke among 10-year survivors of breast cancer. J Clin Oncol 24(34):5388–5394. doi: 10.1200/JCO.2006.06.5516 CrossRefPubMedGoogle Scholar
  4. 4.
    Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12):1135–1141. doi: 10.1016/S1470-2045(10)70257-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA et al (2016) Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156(2):343–349CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 12(12):1101–1108. doi: 10.1016/S1470-2045(11)70270-4 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570. doi: 10.1016/S0140-6736(07)60200-1 CrossRefPubMedGoogle Scholar
  8. 8.
    Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S et al (2017) Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 28(3):487–496. doi: 10.1093/annonc/mdw673 PubMedGoogle Scholar
  9. 9.
    Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ et al (2016) The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Eur J Cancer 68:11–21CrossRefPubMedGoogle Scholar
  10. 10.
    Ligibel JA, James O’Malley A, Fisher M, Daniel GW, Winer EP, Keating NL (2012) Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat 131(2):589–597CrossRefPubMedGoogle Scholar
  11. 11.
    Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE et al (2010) Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 31(9):1142–1148. doi: 10.1093/eurheartj/ehq010 CrossRefPubMedGoogle Scholar
  12. 12.
    Blaes AH, Mulrooney DA, Vogel RI, Peterson BA, Yee D, Neglia JP et al (2014) Arterial elasticity in testicular cancer survivors. J Clin Oncol 32:5Google Scholar
  13. 13.
    Duprez DA, Jacobs DR Jr, Lutsey PL, Bluemke DA, Brumback LC, Polak JF et al (2011) Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol 174(5):528–536. doi: 10.1093/aje/kwr120 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Grey E, Bratteli C, Glasser SP, Alinder C, Finkelstein SM, Lindgren BR et al (2003) Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16(4):265–269CrossRefPubMedGoogle Scholar
  15. 15.
    Hom EK, Duprez DA, Jacobs DR Jr, Bluemke DA, Brumback LC, Polak JF et al (2016) Comparing arterial function parameters for the prediction of coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA). Am J Epidemiol 184(12):894–901CrossRefPubMedGoogle Scholar
  16. 16.
    Shechter M, Matetzky S, Prasad M, Goitein O, Goldkorn R, Naroditsky M et al (2017) Endothelial function predicts 1-year adverse clinical outcome in patients hospitalized in the emergency department chest pain unit. Int J Cardiol 240:14–19CrossRefPubMedGoogle Scholar
  17. 17.
    Shechter M, Issachar A, Marai I, Koren-Morag N, Freinark D, Shahar Y et al (2009) Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol 134(1):52–58. doi: 10.1016/j.ijcard.2008.01.021 CrossRefPubMedGoogle Scholar
  18. 18.
    Hirata Y, Sugiyama S, Yamamoto E, Matsuzawa Y, Akiyama E, Kusaka H et al (2014) Endothelial function and cardiovascular events in chronic kidney disease. Int J Cardiol 173(3):481–486. doi: 10.1016/j.ijcard.2014.03.085 CrossRefPubMedGoogle Scholar
  19. 19.
    Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340(23):1801–1811. doi: 10.1056/NEJM199906103402306 CrossRefPubMedGoogle Scholar
  20. 20.
    Luca MC, Liuni A, Harvey P, Mak S, Parker JD (2016) Effects of estradiol on measurements of conduit artery endothelial function after ischemia and reperfusion in premenopausal women. Can J Physiol Pharmacol 94(12):1304–1308. doi: 10.1139/cjpp-2015-0589 CrossRefPubMedGoogle Scholar
  21. 21.
    Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219. doi: 10.1056/NEJMoa1604700 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD (2016) Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27(1):6–13. doi: 10.1097/EDE.0000000000000394 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Division of Hematology/OncologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Division of CardiologyUniversity of MinnesotaMinneapolisUSA
  3. 3.Division of Gynecology/OncologyUniversity of MinnesotaMinneapolisUSA
  4. 4.Masonic Cancer CenterUniversity of MinnesotaMinneapolisUSA

Personalised recommendations